Tectonic
Tectonic Financial Intelligence is an advanced analytics company leveraging machine learning and native-AI to identify hidden patterns of high-risk, high-impact in the healthcare sector. Over several years of development and significant capital we have developed the DevWatch engine.
Today, we apply DevWatch to the financial markets—specifically to investment strategies tied to clinical stage catalysts. Through Swiss-based financial structures, including Actively Managed Certificates (AMCs), we translate predictive insight into targeted investment opportunities.
Our technology is purpose-built to extract actionable intelligence from fragmented, underappreciated data—enabling investors to make more confident decisions in uncertain markets.
3 Pillar Investing
When AI Commoditizes Public Data, What Still Differentiates Funds?
Public-data edges compress fast. As general-purpose “AI-everywhere” models sweep filings, social feeds, and macro prints within milliseconds, signals converge toward parity. The remaining advantage lies where models can’t easily go: hard-to-replicate derived datasets and domain-bound priors that shape what to ask in the first place.
Clinical-Trial Reliability as a Market Variable
Markets discount science. They’re slower to discount execution — the day-to-day reliability of trials that decide enterprise value. We treat operational reliability as a first-class market variable and design our exposure accordingly.
Risk Discipline in Catalyst-Driven Markets
Catalysts amplify both alpha and error. We operate within defined bands for position size, exposure, and event windows, and we enforce change-control when models evolve. Principles, not parameters — enough for allocators to assess process without revealing our machinery.
About us
Tectonic Financial Intelligence was founded by clinical trial professionals with over 60 years of combined experience. Our proprietary AI analytical models are informed by extensive historical case studies spanning venture-backed, small-cap, and large pharmaceutical companies globally.
Our founders recognized a recurring pattern of promising assets failing clinical trials not due to inherent limitations of the therapy itself, but rather as a result of suboptimal clinical trial management. This observation led to the development of our unique clinical trial success factors, which have demonstrated a strong correlation with trial and program outcomes.